Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

0.0%

0 terminated out of 18 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

6%

1 trials in Phase 3/4

Results Transparency

50%

6 of 12 completed with results

Key Signals

6 with results100% success

Data Visualizations

Phase Distribution

14Total
Not Applicable (7)
P 1 (2)
P 2 (4)
P 4 (1)

Trial Status

Completed12
Recruiting2
Unknown1
Withdrawn1
Not Yet Recruiting1
Suspended1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 12 completed trials

Clinical Trials (18)

Showing 18 of 18 trials
NCT07507682Not ApplicableRecruiting

Can Astaxanthin Help Manage Asthma in POlluted Areas?

NCT07493629RecruitingPrimary

Immune Status and Disease Control of Inflammatory Airway Diseases

NCT07116460Not ApplicableNot Yet Recruiting

Cost Effective Air Filtration Intervention in Low-Income Housing to Reduce Asthma Morbidity

NCT02767973Not ApplicableSuspendedPrimary

To Identify Persons Who Are Susceptible to WSP-induced Inflammation and Examine the Role of GSTM1 and Other Factors in This Susceptibility

NCT03851406Not ApplicableCompletedPrimary

Woodsmoke Particulate + Hypertonic Saline

NCT03924635Phase 4CompletedPrimary

An Exploratory Study to Characterise Changes in Airway Inflammation, Symptoms, Lung Function and Reliever Use in Adult Asthma Patients

NCT03861390Phase 1CompletedPrimary

Woodsmoke Particulate + Prednisone

NCT00635882Phase 2Completed

Asthma Study Comparing Anti-Inflammatory Effects of 3 Doses of Mometasone Furoate/Formoterol Fumarate and Medium Dose Mometasone Furoate (Study P05122 AM1)(COMPLETED)

NCT03444298Phase 2CompletedPrimary

A Study of Gamma Tocopherol-enriched Supplement on Lower Airway Responses to Inhaled Wood Smoke in Healthy Adults

NCT04885738Unknown

The Value of FeNO in Predicting Airway Eosinophilic Inflammation

NCT00994175Phase 2Completed

A Randomized, Placebo-Controlled, Double-Blind Pilot Study of Pioglitazone Hydrochloride in Severe, Refractory Asthma

NCT00604578Phase 2Withdrawn

Pioglitazone Hydrochloride (Actos(Registered Trademark)) to Treat Asthma

NCT00869596Phase 1CompletedPrimary

Study of Biomarkers of Airway Inflammation (0000-128)

NCT00527345Completed

Children's Exposures/Health Effects/Diesel Exhaust

NCT00455377CompletedPrimary

Lung Function and Airway Inflammation in Portland Cement Workers

NCT00673907Not ApplicableCompletedPrimary

HIPWOODS - Health Effects Related to Exposure to Particle Pollution From Woodburning Stoves

NCT00989365Not ApplicableCompleted

Effect of Aerobic Training on Asthmatic Patients

NCT00814281Not ApplicableCompletedPrimary

Airborne Ultrafine and Fine Particulate Matter: A Cause for Endothelial Dysfunction in Man?

Showing all 18 trials

Research Network

Activity Timeline